Polymorphisms in toll-like receptor 4 and toll-like receptor 9 influence viral load in a seroincident cohort of HIV-1-infected individuals

AIDS

Volumn 23, Issue 18, 2009, Pages 2387-2395

  Pine, Samuel O ^a,c   McElrath, M Juliana ^a,b,c   Bochud, Pierre Yves ^c,d,e  

^a Department of Global Health   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

HIV genetics; HIV immunology; HIV 1; Innate immunity; Single nucleotide polymorphism; Toll like receptor 4; Toll like receptor 9

Indexed keywords

ANTIRETROVIRUS AGENT; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CELL COUNT; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; GROUPS BY AGE; HAPLOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS LOAD;

ADULT; ALGORITHMS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; POLYMORPHISM, GENETIC; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 3; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTOR 9; VIRAL LOAD;

EID: 72949104926     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328330b489     Document Type: Article

References (62)

1. Buchbinder S, Vittinghoff E. HIV-infected long-term nonpro-gressors: epidemiology, mechanisms of delayed progression, and clinical and research implications. Microbes Infect 1999; 1:1113-1120.
2. Buchbinder SP, Katz MH, Hessol NA, O'Malley PM, Holmberg SD. Long-term HIV-1 infection without immunologic progression. AIDS 1994; 8:1123-1128.
3. Cao Y, Qin L, Zhang L, Safrit J, Ho DD. Virologic and immu-nologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med 1995; 332:201-208.
4. Pereyra F, Addo MM, Kaufmann DE, Liu Y, Miura T, Rathod A, et al. Genetic and immunologic heterogeneity among persons who control HIV infection in the absenceof therapy. J Infect Dis 2008; 197:563-571.
5. Navis M, Schellens I, van Baarle D, Borghans J, van Swieten P, Miedema F, et al. Viral replication capacity as a correlate of HLA B57/B5801-associated nonprogressive HIV-1 infection. J Immunol 2007; 179:3133-3143.
6. R T-cell-mediated selective pressure on human immunodeficiency virus type 1 nef in HLA-BM57R elite suppressors. J Virol 2009; 83:88-97.
7. Carrington M, Nelson GW, Martin MP, Kissner T, Vlahov D, Goedert JJ, et al. HLA and HIV-1: heterozygote advantage and BM35-CwM04 disadvantage. Science 1999; 283:1748-1752.
8. Itescu S, Mathur-Wagh U, Skovron ML, Brancato LJ, Marmor M, Zeleniuch-Jacquotte A, Winchester R. HLA-B35 is associated with accelerated progression to AIDS. J Acquir Immune Defic Syndr 1992; 5:37-45.
9. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006; 443:350-354.
10. R T cells correlates with disease progression and defines a reversible immune dysfunction. Nat Immunol 2007; 8:1246-1254.
11. R T-cell exhaustion in typical progressors but not in long-term nonprogressors. Blood 2007; 109:4671-4678.
12. R T-cell clones correlates with the clinical state of human immunodeficiency virus type 1 (HIV-1)-infected individuals and may be responsible for blocking infection with nonsyncytium-inducing HIV-1 in vitro. J Virol 1998; 72:876-881.
13. Flores-Villanueva PO, Hendel H, Caillat-Zucman S, Rappaport J, Burgos-Tiburcio A, Bertin-Maghit S, et al. Associations of MHC ancestral haplotypes with resistance/susceptibility to AIDS disease development. J Immunol 2003; 170:1925-1929.
14. Kiepiela P, Leslie AJ, Honeyborne I, Ramduth D, Thobakgale C, Chetty S, et al. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature 2004; 432:769-775.
15. Migueles SA, Sabbaghian MS, Shupert WL, Bettinotti MP, Marincola FM, Martino L, et al. HLA BM5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc Natl Acad Sci U S A 2000; 97:2709-2714.
16. Tang J, Costello C, Keet IP, Rivers C, Leblanc S, Karita E, et al. HLA class I homozygosity accelerates disease progression in human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses 1999; 15:317-324.
17. Gonzalez E, Dhanda R, Bamshad M, Mummidi S, Geevarghese R, Catano G, et al. Global survey of genetic variation in CCR5, RANTES, and MIP-1alpha: impact on the epidemiology of the HIV-1 pandemic. Proc Natl Acad Sci U S A 2001; 98:5199-5204.
18. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicen-ter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996; 273:1856-1862.
19. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006; 124:783-801.
20. Bochud PY, Bochud M, Telenti A, Calandra T. Innate immu-nogenetics: a tool for exploring new frontiers of host defence. Lancet Infect Dis 2007; 7:531-542.
21. Misch EA, Hawn TR. Toll-like receptor polymorphisms and susceptibility to human disease. Clin Sci (Lond) 2008; 114:347-360.
22. Tulic MK, Hurrelbrink RJ, Prele CM, Laing IA, Upham JW, Le Souef P, et al. TLR4 polymorphisms mediate impaired responses to respiratory syncytial virus and lipopolysaccharide. J Immunol 2007; 179:132-140.
23. Tal G, Mandelberg A, Dalal I, Cesar K, Somekh E, Tal A, et al. Association between common toll-like receptor 4 mutations and severe respiratory syncytial virus disease. J Infect Dis 2004; 189:2057-2063.
24. Bochud PY, Hersberger M, Taffe P, Bochud M, Stein CM, Rodrigues SD, et al. Polymorphisms in toll-like receptor 9 influence the clinical course of HIV-1 infection. AIDS 2007; 21:441-446.
25. Hawn TR, Wu H, Grossman JM, Hahn BH, Tsao BP, Aderem A. A stop codon polymorphism of toll-like receptor 5 is associated with resistance to systemic lupus erythematosus. Proc Natl Acad Sci U S A 2005; 102:10593-10597.
26. Wurfel MM, Gordon AC, Holden TD, Radella F, Strout J, Kajikawa O, et al. Toll-like receptor 1 polymorphisms affect innate immune responses and outcomes in sepsis. Am J Respir Crit Care Med 2008; 178:710-720.
27. Oh DY, Taube S,HamoudaO, KuchererC,PoggenseeG,Jessen H, et al. A Functional toll-like receptor 8 variant is associated with HIV disease restriction. J Infect Dis 2008; 198:701-709.
28. Martinelli E, Cicala C, Van Ryk D, Goode DJ, Macleod K, Arthos J, Fauci AS. HIV-1 gp120 inhibits TLR9-mediated activation and IFN-{alpha} secretion in plasmacytoid dendritic cells. Proc Natl Acad Sci U S A 2007; 104:3396-3401.
29. Heil F, Ahmad-Nejad P, Hemmi H, Hochrein H, Ampenberger F, Gellert T, et al. The toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur J Immunol 2003; 33:2987-2997.
30. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004; 303:1526-1529.
31. Jiang W, Lederman MM, Mohner RJ, Rodriguez B, Nedrich TM, Harding CV, Sieg SF. Impaired naive and memory B-cell responsiveness to TLR9 stimulation in human immunodeficiency virus infection. J Virol 2008; 82:7837-7845.
32. Mandl JN, Barry AP, Vanderford TH, Kozyr N, Chavan R, Klucking S, et al. Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpatho-genic AIDS virus infections. Nat Med 2008; 14:1077-1087.
33. Soriano-Sarabia N, Vallejo A, Ramirez-Lorca R, Rodriguez MD, Salinas A, Pulido I, et al. Influence of the toll-like receptor 9 1635A/G polymorphism on the CD4 count, HIV viral load, and clinical progression. J Acquir Immune Defic Syndr 2008; 49:128-135.
34. Sebastiani P, Lazarus R, Weiss ST, Kunkel LM, Kohane IS, Ramoni MF. Minimal haplotype tagging. Proc Natl Acad Sci U S A 2003; 100:9900-9905.
35. Halldorsson BV, Istrail S, De La Vega FM. Optimal selection of SNP markers for disease association studies. Hum Hered 2004; 58:190-202.
36. Schacker T, Collier AC, Hughes J, Shea T, Corey L. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med 1996; 125:257-264.
37. Stekler J, Sycks BJ, Holte S, Maenza J, Stevens CE, Dragavon J, et al. HIV dynamics in seminal plasma during primary HIV infection. AIDS Res Hum Retroviruses 2008; 24:1269-1274.
38. Mulder J, McKinney N, Christopherson C, Sninsky J, Greenfield L, Kwok S. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J Clin Microbiol 1994; 32:292-300.
39. Schacker TW, Hughes JP, Shea T, Coombs RW, Corey L. Biological and virologic characteristics of primary HIV infection. Ann Intern Med 1998; 128:613-620.
40. Patke DS, Langan SJ, Carruth LM, Keating SM, Sabundayo BP, Margolick JB, et al. Association of Gag-specific T lymphocyte responses during the early phase of human immunodeficiency virus type 1 infection and lower virus load set point. J Infect Dis 2002; 186:1177-1180.
41. Gilbert PB. Some statistical issues in the design of HIV-1 vaccine and treatment trials. Stat Methods Med Res 2000; 9:207-229.
42. Speelmon EC, Livingston-Rosanoff D, Li SS, Vu Q, Bui J, Geraghty DE, et al. Genetic association of the antiviral restriction factor TRIM5alpha with human immunodeficiency virus type 1 infection. J Virol 2006; 80:2463-2471.
43. Urassa W, Bakari M, Sandstrom E, Swai A, Pallangyo K, Mbena E, et al. Rate of decline of absolute number and percentage of CD4 T lymphocytes among HIV-1-infected adults in Dar es Salaam, Tanzania. AIDS 2004; 18:433-438.
44. StormN, Darnhofer-PatelB,van den BoomD,Rodi CP. MALDI-TOF mass spectrometry-based SNP genotyping. Methods Mol Biol 2003; 212:241-262.
45. Zhao LP, Li SS, Khalid N. A method for the assessment of disease associations with single-nucleotide polymorphism hap-lotypes and environmental variables in case-control studies. Am J Hum Genet 2003; 72:1231-1250.
46. Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JN, Jones M, et al. TLR4 mutations are associated with endotoxin hypore-sponsiveness in humans. Nat Genet 2000; 25:187-191.
47. Awomoyi AA, Rallabhandi P, Pollin TI, Lorenz E, Sztein MB, Boukhvalova MS, et al. Association of TLR4 polymorphisms with symptomatic respiratory syncytial virus infection in high-risk infants and young children. J Immunol 2007; 179:3171-3177.
48. Mockenhaupt FP, Cramer JP, Hamann L, Stegemann MS, Eckert J, Oh NR, et al. Toll-like receptor (TLR) polymorphisms in African children: common TLR-4 variants predispose to severe malaria. Proc Natl Acad Sci U S A 2006; 103:177-182.
49. Bochud PY, Chien JW, Marr KA, Leisenring WM, UptonA, Janer M, et al. Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med 2008; 359:1766-1777.
50. Ferwerda B, McCall MB, Verheijen K, Kullberg BJ, van der Ven AJ, Van der Meer JW, Netea MG. Functional consequences of toll-like receptor4 polymorphisms. Mol Med 2008; 14:346-352.
51. Ferwerda B, Kibiki GS, Netea MG, Dolmans WM, van der Ven AJ. The toll-like receptor 4 Asp299Gly variant and tuberculosis susceptibility in HIV-infected patients in Tanzania. AIDS 2007; 21:1375-1377.
52. Cooke KR, Olkiewicz K, Erickson N, Ferrara JL. The role of endotoxin and the innate immune response in the pathophy-siology of acute graft versus host disease. J Endotoxin Res 2002; 8:441-448.
53. Schietroma M, Cappelli S, Carlei F, Di Giuro G, Agnifili A, Recchia CL, et al. Intestinal and systemic endotoxaemia after laparotomic or laparoscopic cholecystectomy [in Italian]. Chir Ital 2006; 58:171-177.
54. Wellmann W,Fink PC, BennerF,Schmidt FW. Endotoxaemia in active Crohn's disease. Treatment with whole gut irrigation and 5-aminosalicylic acid. Gut 1986; 27:814-820.
55. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365-1371.
56. Funderburg N, Luciano AA, Jiang W, Rodriguez B, Sieg SF, Lederman MM. Toll-like receptor ligands induce human T cell activation and death, a model for HIV pathogenesis. PLoS ONE 2008; 3:e1915.
57. BrandlK, PlitasG,SchnablB,DeMatteo RP, Pamer EG. MyD88-mediated signals induce the bactericidal lectin RegIII gamma and protect mice against intestinal Listeria monocytogenes infection. J Exp Med 2007; 204:1891-1900.
58. Cash HL, Whitham CV, Behrendt CL, Hooper LV. Symbiotic bacteria direct expression of an intestinal bactericidal lectin. Science 2006; 313:1126-1130.
59. Pamer EG. TLR polymorphisms and the risk of invasive fungal infections. N Engl J Med 2008; 359:1836-1838.
60. Alcabes P, Pezzotti P, Phillips AN, Rezza G, Vlahov D. Long-term perspective on the prevalent-cohort biases in studies of human immunodeficiency virus progression. Am J Epidemiol 1997; 146:543-551.
61. Brookmeyer R, Gail MH, Polk BF. The prevalent cohort study and the acquired immunodeficiency syndrome. Am J Epidemiol 1987; 126:14-24.
62. Tao K, Fujii M, Tsukumo S, Maekawa Y, Kishihara K, Kimoto Y, et al. Genetic variations of toll-like receptor 9 predispose to systemic lupus erythematosus in Japanese population. Ann Rheum Dis 2007; 66:905-909.